Everything below concerns reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
== Selected works == Approximately complete analyses of thirty "normal" urines (1905) Chemical problems in hospital practice (1908) Nitrogen retention in the blood in experimental acute nephritis in the cat (1912) Preservatives and other chemicals in foods: Their use and abuse (1914) On the determination of creatinine and creatine in urine (1914) Recent biochemical investigations on blood and urine;: Their bearing on clinical and experimental medicine (1917) A System of Blood Analysis by Folin and Wu (1919) Laboratory Manual of Biological Chemistry with Supplement (1925)
PD-L1, an immunosuppressive PD-1 ligand, is highly expressed in several cancers; the role of PD-1 in cancer immune evasion is well established. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. Inhibition of the interaction between PD-1 and PD-L1 can enhance T-cell responses in vitro and mediate preclinical antitumor activity. This is known as immune checkpoint blockade. PD-1 is expressed intrinsically in some tumor cells, such as melanoma, where it promotes tumor growth independently of the immune system. Inhibition of tumor cell-intrinsic PD-1 suppresses tumor growth, whereas overexpression or engagement by PD-L1 enhances tumorigenicity. Combination therapy using both anti-PD1 along with anti-CTLA4 therapeutics have emerged as important tumor treatments within the field of checkpoint inhibition. The effects of the two antibodies has been shown to be more effective than either antibody alone and does not appear to be redundant. Anti-CTLA4 treatment leads to an enhanced antigen specific T cell dependent immune reaction while anti-PD-1 appears to reactivate CD8+ T cells ability to lyse cancer cells. In clinical trials, combination therapy has been shown to be effective in reducing tumor size in patients that are unresponsive to single co-inhibitory blockade, despite increasing levels of toxicity due to anti-CTLA4 treatment. A combination of PD1 and CTLA4 induced up to a ten-fold higher number of CD8+ T cells that are actively infiltrating the tumor tissue.
==== Reticular region ==== The reticular region lies deep in the papillary region and is usually much thicker. It is composed of dense irregular connective tissue, and receives its name from the dense concentration of collagenous, elastic, and reticular fibres that weave throughout it. These protein fibres give the dermis its properties of strength, extensibility, and elasticity. Also located within the reticular region are the roots of the hairs, sebaceous glands, sweat glands, receptors, nails, and blood vessels. Tattoo ink is held in the dermis. Stretch marks, often from adolescent growth spurts, weight gain, pregnancy and obesity, are also located in the dermis.
Studies show that the EPOC effect exists after both aerobic exercise and anaerobic exercise. In a 1992 Purdue study, results showed that high intensity, anaerobic type exercise resulted in a significantly greater magnitude of EPOC than aerobic exercise of equal work output. For exercise regimens of comparable duration and intensity, aerobic exercise burns more calories during the exercise itself, but the difference is partly offset by the higher increase in caloric expenditure that occurs during the EPOC phase after anaerobic exercise. Anaerobic exercise in the form of high-intensity interval training was also found in one study to result in greater loss of subcutaneous fat, even though the subjects expended fewer than half as many calories during exercise. Whether this result was caused by the EPOC effect has not been established, and the caloric content of the participants' diet was not controlled during this particular study period. Most researchers use a measure of EPOC as a natural part of the quantification or measurement of exercise and recovery energy expenditure; to others this is not deemed necessary. After a single bout or set of weight lifting, Scott et al. found considerable contributions of EPOC to total energy expenditure. In their 2004 survey of the relevant literature, Meirelles and Gomes found: "In summary, EPOC resulting from a single resistance exercise session (i.e., many lifts) does not represent a great impact on energy balance; however, its cumulative effect may be relevant".
== Lecturing and media == Pert lectured worldwide on peptide and other subjects, including her theories on emotions and mind-body communication. Her popular book, Molecules of Emotion: Why You Feel the Way You Feel, (Scribner, 1997) expounded on her research and theories. She was featured in Washingtonian magazine (December 2001) as one of Washington's fifty "Best and Brightest" individuals. The Sydney Morning Herald profiled Pert in 2004:
Sources: en.wikipedia.org
The outer layer, or subintima, can be of almost any type of connective tissue – fibrous (dense collagenous type), adipose (fatty; e.g. in intra-articular fat pads) or areolar (loose collagenous type). The inner layer (in contact with synovial fluid), or intima, consists of a sheet of cells thinner than a piece of paper. Where the underlying subintima is loose, the intima sits on a pliable membrane, giving rise to the term synovial membrane. This membrane, together with the cells of the intima, provides something like an inner tube, sealing the synovial fluid from the surrounding tissue (effectively stopping the joints from being squeezed dry when subject to impact, such as running). Just outside the intima, most synovium has a dense net of fenestrated small blood vessels that provide nutrients not only for synovium but also for the avascular cartilage. In any one position, much of the cartilage is close enough to get nutrition directly from the synovium. Some areas of cartilage have to obtain nutrients indirectly and may do so either from diffusion through cartilage or possibly by 'stirring' of synovial fluid. The surface of synovium may be flat or may be covered with finger-like projections or villi, which, it is presumed, help to allow the soft tissue to change shape as the joint surfaces move one on another. The synovial fluid can be thought of as a specialized fluid form of synovial extracellular matrix rather than a secretion in the usual sense.
Intensive weight training causes micro-tears to the muscles being trained; this is generally known as microtrauma. These micro-tears in the muscle contribute to the soreness felt after exercise, called delayed onset muscle soreness (DOMS). It is the repair of these micro-traumas that results in muscle growth. Normally, this soreness becomes most apparent a day or two after a workout. However, as muscles become adapted to the exercises, soreness tends to decrease. Weight training aims to build muscle by prompting two different types of hypertrophy: sarcoplasmic and myofibrillar. Sarcoplasmic hypertrophy leads to larger muscles and so is favored by bodybuilders more than myofibrillar hypertrophy, which builds athletic strength. Sarcoplasmic hypertrophy is triggered by increasing repetitions, whereas myofibrillar hypertrophy is triggered by lifting heavier weight. In either case, there is an increase in both size and strength of the muscles (compared to what happens if that same individual does not lift weights at all), although the emphasis is different. It is important for bodybuilders to train in a manner which keeps their joints strong and reduces the risk of wear and tear injuries from weight training. This means developing muscular strength in a way which does not misalign (decentrate) the joint but causes it to be optimally positioned and aligned (centrated). As considered by physical therapist Chad Waterbury:
Excerpts appearing later that year on the Showtime cable network included a performance of "China Grove". The successful 1987 reunion sparked discussions about reconstituting the band on a permanent basis. They eventually decided to replicate the Toulouse Street/The Captain and Me incarnation, settling on a lineup featuring Johnston, Simmons, Hartman, Porter and Hossack, plus more recent addition LaKind, and released Cycles on Capitol Records in 1989. The album featured a Top 10 single, "The Doctor". The song is very similar to "China Grove", and the connection was further enhanced by guest Bill Payne's tinkling piano. Other material on the album included Johnston's "South of the Border", Dale Ockerman's and Pat Simmons' "Take Me to the Highway", and "I Can Read Your Mind", a version of the Isley Brothers' "Need a Little Taste of Love", and a version of the Four Tops classic, "One Chain (Don't Make No Prison)", which had been covered by Santana years before. Cycles proved a successful comeback album and was certified Gold. Bumpus participated in the 1989 and 1990 tours, adding his distinctive voice, keyboards, saxophone and flute. His presence bridged the gap between the current band and the McDonald era; he sang lead vocals on "One Step Closer" (as he originally had on the 1980 album) while Simmons took McDonald's part. The group was further augmented on the 1989 tour by Dale Ockerman (keyboards, guitar, backing vocals), Richard Bryant (percussion, vocals) and Jimi Fox (percussion, backing vocals).
=== Breastfeeding === Paracetamol is excreted in breast milk at measurable concentrations (milk/plasma ratio approximately 1), but the amount ingested by the infant is much lower than paediatric therapeutic doses and rarely associated with clinical effects. Use during breastfeeding is considered compatible at recommended doses, with extra caution for preterm infants or infants with liver disease.
== In polymer physics == In some scientific areas such as polymer physics, one may consider a chain of points and links between consecutive points. If the points are sequentially numbered and located at positions r1, r2, r3, etc. then bond vectors are defined by u1=r2−r1, u2=r3−r2, and ui=ri+1−ri, more generally. This is the case for kinematic chains or amino acids in a protein structure. In these cases, one is often interested in the half-planes defined by three consecutive points, and the dihedral angle between two consecutive such half-planes. If u1, u2 and u3 are three consecutive bond vectors, the intersection of the half-planes is oriented, which allows defining a dihedral angle that belongs to the interval (−π, π]. This dihedral angle is defined by
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.